George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
For anyone wondering what one rns can do check out iqai, I hold at 5p ish. Don’t see any reason why the same can’t happen here with our basket of tests!
Trek
Just to add, for a takeover of ONC. It doesnt get anymore straightforward. It’s just a bolt on division with any R&D dept financing it. AZN, ROCH, MERCK, BMS, GENENTECH the list goes on. ONC could add significant value to any R&D division and the outsourcing would self fund in no time.
Trek
Hi Guys,
Just looked in. Next tick up looks to be on as I type, it’s back to 180. Remember director options only start at £2.
The market can sometimes be a little myopic with headline losses. The two key numbers from the presentation were, ops will cost £6m per year going forward. I assume that’s pay and non pay (capex costs are very small). They have line of sight to £56m of rev’s. I assume given that that is a published number it will be well understated!
Adam also made it clear China and Russia EarlyCDT lung was still on. They were confident of making up covid time. Progress was also being made with Breast, Ovarian and Prostrate early cancer detection and we will hear more soon. Add that to Liver and Lung and you have a very comprehensive all in one cancer early warning system. 4years advance notice and the ability to tailor drugs to target the patients individually saving pts heartache and Pharma millions in drug diagnostics! Plus add in covid tests and covid subsequent diseases.
They key risk here was a cheap takeover as they were partnering so many big Pharma’s. They know what ONC have.
I was a holder of both HZD and LID but bailed for other opportunities having waited and waited for a takeover. You can see my posts there, LID I picked up as a covid play around March and HZD I traded in and out for over 2 years. HZD’s results were poor and LID just never seemed to happen so I eventually sold having done ok in both.
I am not saying that a t/o is on the cards here but what I will say is if one Pharma co bids another may be fretful that their programs could receive less priority and also bid! The databank they have is huge and will be coveted.
I don’t get why peeps chance some other v high risk covid plays all in when here you can see similar upsides over time with less risk.
Usual caveats
Trek
Nice to see us on the uptrend. Still under the radar.
Trek - thanks for comments on the interview and what is in the pipeline.
Financial results were a little disappointing as with so much going on I was hoping for more especially from collaborations with Roche and Genentech. Revenue suggests initial payments from deals are low but hopefully the later payments will be significantly more. News on some of these is due this month. Overall a lot is going on and in spite of the SP blip last week, I feel optimistic. Being a world leader must count for something and a premium on their work justified. Added recently and now await developments.
Note HZD received an offer announced today at 108% premium to SP. ONC might be a target for a large Pharma which adds a dimension to being an attractive investment.
TrekM - When do you see the next tick up here? The results post end of May would be much better than what we say last RNS. What do you think the news flow will be here. ?
I have just listened to the interview, now published. I am more than happy with my investments here. What a fantastic presentation from a pioneering world leader in immune biomarkers. There is no other....
Here is a tasted of the commercials to look forward to from slide 8...
Validated commercial position
- Five ongoing contracted projects with the world’s largest/leading pharma
- £14M gross value in unconverted pipeline
- £42M product sales commitments
Their contracts with big Pharma and NHS are frankly staggering!
Enjoy..
https://www.investormeetcompany.com/investor/meeting/full-year-results-for-the-year-ended-31-may-2020/presentation
Trek
The price of shares in AIM-listed immunodiagnostics specialist Oncimmune (LON:ONC) dropped by 8.90% to 161.70p (as of 15:10 GMT) after its pre-tax loss for the year ended 31st May broadened. Revenues grew significantly and further major agreements have been reached since the end of the period, but costs are still significantly above income.
CEO Dr Adam Hill commented: “We have made strong progress in our first full year of trading since the launch of our three-year strategy in September 2018, which has delivered a step-change in our revenue growth over the year led by the ImmunoINSIGHTS services business. Despite the impact of COVID-19, further positive news flow post year end has sustained the Group’s growth trajectory throughout H1 2021.
“Following the successful turnaround, Oncimmune now has a solid platform business underpinned by its core technology and expertise, that is validated by an expanding stable of commercial contracts and a full pipeline of pharma service opportunities. This underpins our expectation of delivering substantial further growth in the re-focused business throughout FY 2021 and beyond, about which the Company looks forward to providing further progress updates“.
https://masterinvestor.co.uk/financial-news/oncimmune-losses-drive-down-shares/?mc_cid=2eb1a06410&mc_eid=418bda054f
Trek
No I know , always off load on a positive day once content with gains
Hi Gilers1,
I also have a decent position here and will be adding again soon. However, just for transparency, be warned that you may find that you cannot sell anything significant in a hurry. I often run dummy buy/sell trades to understand liquidity and it’s often been a nightmare to buy or sell here.
It’s another reason why one has to get in early so you can derisk into news while there are buyers. I traded this in the 120’s to grab a few extra. It wasn’t worth the effort!
Atb
Trek
Ok cheers for the input, I’m quite a large holder and looking forward to next 12 months
Hi Gilers1.
Yes loss has widened but rev’s are increasing. cost increases are accretive and R&D related. Numbers can be spun either way. I know that. IMO these are not lipstick on a pig figures. They have currency behind them. It’s normal growth.
As for the market being short sighted. Well, that is difficult to tell. Volumes don’t indicate a sell off and this is a volatile stock. I watched it drop 12p on a 3k trade this week and then recover. Today has been far from a sell off. The biggest trade was TNCP, 30k and it was a duplicate trade. Probably just moved across books as MM’s don’t have stock.
https://api.londonstockexchange.com/api/gw/lse/download/ONC/trades
I get the profit taking but for me that time is not yet. There’s plenty of legs in this one. The newsflow has been excellent, the numbers on contracts even if just guidance can defo be improved though. The big Pharma companies check out the finances of any company before they enter into a contract. And for ONC to be discussing acquisitions they have the fundamentals in place to even contemplate that.
Usual caveats
Trek
And the market I guess is short sighted and just reacts to the widening loss
Absolutely. I have been here many times before and it’s the time to be here at ground level. Don’t forget we’ve motored from 60p to here. There’s bound to be profit taking.
I missed the call, had to go out but will listen later.
I sold other stocks to add to my position here and still think that that’s the right call and will be adding again.
Director options are 200p. Sp is illiquid so moves on low volume. A 10-20% swing is not a lot and can bounce back easily. TA still bullish as well. Not many companies winning contracts hand over fist atm!
Trek
So u presume no revenues have been generated yet from the below
EarlyCDT Lung blood test now has 19 commercial distribution and partnership agreements covering 24 countries with a significant order book of minimum sales commitments from distributors secured.
TrekMadone,
Made a big loss and i was expecting more from the contracts, market reacted negatively. Going forward, we won't get the value of the contract either when we get NHS for example and that will not add much to our share price.
Big if profit taking. I think we’ll see some director buys now out of close period.
Regular income, contracts landed risk to upside from here.
Trek
Obviously the market was expecting more immediate cash impact from contracts. I read it as that will be due the second half. £1.2m is a massive step up on 2019 and as you can see £511k came in just before the cut off. I expect there is more that missed, would have helped if that could be clear in guidance.
Overall loss of £8.5m a slight increase but they made an acquisition. It’s now clear that all the RCF was used and they now have another €6m, €3m of which has been used. Looks like the model of servicing the debt from revs and using the flex is working.
Cash of £4.2m and net debt of £3m is a turnaround from an overall cash position last year but growth has a price. That’s why the guidance would have helped ‘a step change in revenue growth’ still leaves me guessing a bit but that’s the nature of the beast!
The group is confident that they have enough working capital and are looking at acquisitions as well as organic growth. It’s clear the contracts they have delivered have sustainable predictable revenue streams. They are working out their ‘optimal capital base’, I think there has been a bit of an unknown based on so many late stage discussions particularly with the immunoinsights programs.
My translation of ‘optimal capital base’ is we have a lot going on how much does it cost to run bau, service debt and then how much have we got left for our growth program. That’s actually pretty basic management, I think it’s forgivable given the timings, the pace of growth and govt contracts and financing. Doing all what they are doing and cost savings makes me wonder if the team is big enough.
Anyways I don’t see any need for a raise as ops are covered by revenues and a serviceable RCF. If an acquisition opportunity came up then obviously they may come to the market.
As for the operational side of things. The contract, the growth the innovation etc it’s been absolutely outstanding! As always though it comes back to the money and imo they have done well. So many companies would have taken the easy path of dilution. These haven’t. Congratulations on the results
Atm the market thinks otherwise. Fine by me. I will be buying more.
Usual caveats
Trek